Revascularization for cardiogenic shock

QJM: An International Journal of Medicine

Volumn 94, Issue 2, 2001, Pages 57-67

  Davies, C H ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; CATECHOLAMINE; INOTROPIC AGENT; NICORANDIL; VERAPAMIL;

AORTA BALLOON; BLOOD CLOT LYSIS; BLOOD VESSEL INJURY; CARDIOGENIC SHOCK; CARDIOVASCULAR SYSTEM; DEATH; ECHOCARDIOGRAPHY; HEART ASSIST DEVICE; HEART INFARCTION; HEART INJURY; HEART LEFT VENTRICLE; HEART MUSCLE CELL; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HUMAN; MICROVASCULATURE; MORTALITY; MUSCLE NECROSIS; NEUROENDOCRINE SYSTEM; NEUTROPHIL; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REPERFUSION INJURY; REVASCULARIZATION; REVIEW; SALVAGE THERAPY; SYSTOLIC BLOOD PRESSURE; THROMBOCYTE FUNCTION;

EID: 0035109498     PISSN: 14602725     EISSN: None     Source Type: Journal    
DOI: 10.1093/qjmed/94.2.57     Document Type: Review

References (96)

1. Temporal trends in cardiogenic shock complicating acute myocardial infarction
2. Contemporary reperfusion therapy for cardiogenic shock: The GUSTO-I trial experience. The GUSTO-I Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries
3. Influence of recanalisation therapy on prognosis of cardiogenic shock in acute myocardial infarction in unselected patients of the MITRA-study
4. The in-hospital development of cardiogenic shock after myocardial infarction: Incidence, predictors of occurrence, outcome and prognostic factors
5. Cardiogenic shock complicating acute myocardial infarction in patients without heart failure on admission: Incidence, risk factors and outcome
6. Cardiogenic shock complicating acute myocardial infarction: Predictors of death. GUSTO Investigators. Global Utilization of Streptokinase and Tissue-Plasminogen Activator for Occluded Coronary Arteries
7. Current spectrum of cardiogenic shock and effect of early revascularization on mortality. Results of an International Registry
8. Cardiogenic shock (CS) complicating acute MI-etiologies, management and outcome; Overall findings of the Shock trial registry
9. Quantitative study of infarcted myocardium in cardiogenic shock
10. Acute myocardial infarction treated with intracoronary streptokinase: A report of the Society for Cardiac Angiography
11. Cardiogenic shock in patients with acute ischaemic syndromes with and without ST segment elevation
12. Overcoming thrombolytic resistance: Rationale and initial clinical experience combining thrombolytic therapy and glycoprotein IIb/IIIa receptor inhibition for acute myocardial infarction
13. Hemodynamic, mechanical and metabolic determinants of thrombolytic efficacy: A theoretic framework for assessing the limitations of thrombolysis in patients with cardiogenic shock
14. The effects of intra-aortic counterpulsation on cardiac performance and metabolism in shock associated with acute myocardial infarction
15. Dependence of blood clot lysis on the mode of transport of urokinase into the clot - A magnetic resonance imaging study in vitro
16. Hemodynamic changes determine the efficacy of thrombolysis: Results from an in-vitro flow model
17. Marked systemic hypotension depresses coronary thrombolysis induced by intracoronary administration of recombinant tissue-type plasminogen activator
18. Arterial diastolic pressure augmentation by intraaortic balloon counterpulsation enhances the onset of coronary artery reperfusion by thrombolytic therapy
19. Kinetics of activation of human plasminogen by different activator species at pH 7.4 and 37 degrees C
20. Myocardial changes associated with cardiogenic shock
21. Pathophysiology of cardiogenic shock: Quantitation of myocardial necrosis, clinical, pathologic and electrocardiographic correlations
22. Medical and cellular implications of stunning, hibernation, and preconditioning: An NHLBI workshop
23. Effect of reperfusion on biventricular function and survival after right ventricular infarction
24. Plasma adrenaline and noradrenaline concentrations and dopamine-beta-hydroxylase activity in myocardial infarction with and without cardiogenic shock
25. Severe diffuse hypokinesis of the remote myocardium - The main cause of cardiogenic shock? An echocardiographic study of 75 patients with extremely large myocardial infarctions
26. Value of early two dimensional echocardiography in patients with acute myocardial infarction
27. Prognostic implications and predictors of enhanced regional wall motion of the noninfarct zone after thrombolysis and angioplasty of acute myocardial infarction
28. Ventricular dysfunction and necrosis produced by adrenochrome metabolite of epinephrine: Relation to pathogenesis of catecholamine cardiomyopathy
29. Focal myocarditis associated with pheochromocytoma
30. Reperfusion injury: Experimental evidence and clinical implications
31. Rational basis for use of sodium-hydrogen exchange inhibitors in myocardial ischemia
32. Progression of myocardial necrosis during reperfusion of ischemic myocardium
33. Effects of dobutamine in patients with acute myocardial infarction
34. Combined hemodynamic effects of dopamine and dobutamine in cardiogenic shock
35. Additive effects of dobutamine and amrinone on myocardial contractility and ventricular performance in patients with severe heart failure
36. Mechanisms of beta-adrenoceptor desensitisation in the failing human heart
37. Effects of combined dopamine and nitroprusside therapy in patients with severe pump failure and hypotension complicating acute myocardial infarction
38. Circulatory support for cardiogenic shock due to acute myocardial infarction: A Canadian experience
39. Primary cardiogenic shock during acute myocardial infarction: Results of emergency cardiac transplantation
40. Cardiogenic shock: Survival rates from the national registry for emergency cardiopulmonary bypass investigators
41. Poor outcome with left ventricular assist devices as a bridge to transplant following myocardial infarction with cardiogenic shock
42. Cardiogenic shock complicating acute myocardial infarction: The use of coronary angioplasty and the integration of the new support devices into patient management
43. A randomized evaluation of early revascularization to treat shock complicating acute myocardial infarction. The (Swiss) Multicenter Trial of Angioplasty for Shock-(S)MASH
44. Clinical features of sudden obstruction of the coronary arteries
45. Indications for fibrinolytic therapy in suspected acute myocardial infarction: Collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients
46. Thrombolysis for acute myocardial infarction
47. Long-term effects of intravenous thrombolysis in acute myocardial infarction: Final report of the GISSI study
48. Six-month survival in 20 891 patients with acute myocardial infarction randomized between alteplase and streptokinase with or without heparin
49. Anonymous-Randomised, double-blind comparison of reteplase double-bolus administration with streptokinase in acute myocardial infarction (INJECT): Trial to investigate equivalence. International Joint Efficacy Thrombolytics
50. Frequency and clinical outcome of cardiogenic shock during acute myocardial infarction among patients receiving reteplase or alteplase. Results from GUSTO-III. Global Use of Strategies to Open Occluded Coronary Arteries
51. Intra-aortic balloon counterpulsation in cardiogenic shock. Report of a co-operative clinical trial
52. Intraaortic balloon counterpulsation with and without reperfusion for myocardial infarction shock
53. Intraaortic balloon counterpulsation in patients in cardiogenic shock, medically refractory left ventricular failure and/or recurrent ventricular tachycardia
54. Effectiveness of intraaortic balloon pumping without cardiac surgery for patients with severe heart failure secondary to a recent myocardial infarction
55. Clinical experience with intra-aortic balloon counterpulsation in 112 consecutive patients
56. Randomized controlled trial of intraaortic balloon counterpulsation in early myocardial infarction with acute heart failure
57. Results of a randomized prospective trial of intraaortic balloon counterpulsation and intravenous nitroglycerin in patients with acute myocardial infarction
58. Use of intraaortic balloon counterpulsation in patients presenting with cardiogenic shock: Observations from the GUSTO-I Study. Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries
59. The use of intraaortic balloon counterpulsation an adjunct to reperfusion therapy in cardiogenic shock
60. Intra-aortic balloon counterpulsation before primary percutaneous transluminal coronary angioplasty reduces catheterization laboratory events in high-risk patients with acute myocardial infarction
61. Intraaortic balloon counterpulsation enhances coronary thrombolysis induced by intravenous administration of a thrombolytic agent
62. Effect of a mechanical vs a pharmacologic increase in aortic pressure on coronary blood flow and thrombolysis induced by IV administration of a thrombolytic agent
63. The use of intraaortic balloon pumping as an adjunct to reperfusion therapy in acute myocardial infarction
64. Incidence and predictors of bleeding after contemporary thrombolytic therapy for myocardial infarction. The Global Utilization of Streptokinase and Tissue Plasminogen activator for Occluded coronary arteries (GUSTO) I Investigators
65. Safety of intraaortic balloon counterpulsation in patients with acute myocardial infarction receiving streptokinase intravenously
66. Treatment strategies for acute myocardial infarction complicated by cardiogenic shock in a community hospital
67. Thrombolysis plus aortic counterpulsation: Improved survival in patients who present to community hospitals with cardiogenic shock
68. Use of intra-aortic balloon counterpulsation in patients with acute myocardial infarction complicated by cardiogenic shock
69. Impact of thrombolysis, aortic balloon counterpulsation and their combination in cardiogenic shock: The SHOCK trial registry
70. Thrombolytic therapy in cardiogenic shock: Effect of increased aortic pressure and rapid tPA administration
71. Early revascularization improves survival in cardiogenic shock complicating acute myocardial infarction
72. Percutaneous transluminal coronary angioplasty in patients with cardiogenic shock
73. Efficacy of percutaneous transluminal coronary angioplasty in patients with acute myocardial infarction complicated by cardiogenic shock
74. Systematic direct angioplasty and stent-supported direct angioplasty therapy for cardiogenic shock complicating acute myocardial infarction: In-hospital and long-term survival
75. Follow-up exercise function in patients presenting with cardiogenic shock and acute transmural myocardial infarction
76. Survival and cardiac event rates in the first year after emergency coronary angioplasty for acute myocardial infarction
77. Trends in cardiogenic shock: Report from the SHOCK trial registry
78. Impact of an aggressive invasive catheterization and revascularization strategy on mortality in patients with cardiogenic shock in the Global Utilization of Streptokinase and Tissue Plasminogen Activator for (GUSTO-I) trial. An observational study
79. One-year survival among patients with acute myocardial infarction complicated by cardiogenics shock, and its relation to early revascularization. Results from GUSTO-1
80. Differences in countries' use of resources and clinical outcome for patients with cardiogenic shock after myocardial infarction: Results from the GUSTO trial
81. Early revascularization in acute myocardial infarction complicated by cardiogenic shock. SHOCK Investigators. Should We Emergently Revascularize Occluded Coronaries for Cardiogenic Shock
82. Synergistic interaction between intracoronary stenting and IIb/IIIa inhibition for improving clinical outcomes in primary angioplasty for cardiogenic shock
83. Cardiogenic shock complicating acute myocardial infarction: A comparison of primary angioplasty versus primary stenting in in-hospital outcomes
84. Coronary stenting in the SHOCK trial
85. Measurement of cardiac reserve in cardiogenic shock: Implications for prognosis and management
86. Adjunctive use of abciximab improves clinical outcomes in acute myocardial infarction patients presenting with cardiogenic shock
87. The effect of a CD11/CD18 inhibitor (Hu23F2G) on infarct size following direct angioplasty: The HALT MI study
88. Total complement inhibition: An effective strategy to limit ischemic injury during coronary revascularization on cardiopulmonary bypass
89. Adenosine as an adjunct to thrombolytic therapy for acute myocardial infarction
90. Intravenous nicorandil can preserve microvascular integrity and myocardial viability in patients with reperfused anterior wall myocardial infarction
91. Beneficial effect of intracoronary verapamil on microvascular and myocardial salvage in patients with acute myocardial infarction
92. Glucose-insulin-potassium for acute myocardial infarction: Remarkable results from a new prospective, randomized trial
93. Sodium-hydrogen exchange inhibition: Novel strategy to prevent myocardial injury following ischaemia and reperfusion
94. GUARD During Ischemia Against Necrosis (GUARDIAN) trial in acute coronary syndromes
95. Protecting the ischaemic and reperfused myocardium in acute myocardial infarction: Distant dream or near reality?
96. Effect of early revascularisation on mortality from cardiogenic shock complicating acute myocardial infarction